Asia Pacific GMP Cytokines Market is expected to reach US$ 33.37 million by 2027

PRESS RELEASE BY The Insight Partners 04 Mar 2021

Share this press on

Growth factor segment bytype is estimated to lead the market growth during the forecast period

According to The Insight Partners market research study of “Asia Pacific GMP Cytokines Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Type, End User and Country.” The Asia Pacific GMP cytokines market is expected to reach US$ 33.37 million by 2027 from US$ 17.27 million in 2019; it is estimated to grow at a CAGR of 8.6% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific GMP cytokines market and the factors driving market along with those that act as hindrances.

The GMP cytokines market, by type, is segmented into TNF, interleukin, growth factor, and others. The growth factors segment held the largest share of the market in 2019, whereas the TNF segment is anticipated to register the highest CAGR in the market during the forecast period. Cytokines play a significant role in regulating innate and adaptive immunity, which enables cells of the immune system to communicate over short distances. The cytokines therapy to activate cancer patients' immune systems has been an essential parameter in the treatment. Several research activities have proved cytokines' ability to limit tumor cell growth by a direct anti-proliferative or pro-apoptotic activity. Moreover, some cytokines indirectly inhibit tumor growth by stimulating the cytotoxic activity of immune cells against tumor cells. Similarly, rising prevalence of autoimmune disorders is expected to impact the adoption of cytokines-based therapeutics positively. As per data revealed by the Australian Institute of Health and Welfare (AIHW), on August 25, 2020, about 456,000 Australians (1.9% of the total population) suffer from rheumatoid arthritis. This effectiveness of cytokines therapies over cancer and autoimmune disorders, coupled with increasing prevalence of the disease, is likely to drive the market by 2027. Additionally, increasing number of investments and collaborations by market players to develop cytokines therapies over chronic disorders are also expected to accelerate the market growth.

The growth of the Asia Pacific gmp cytokines market is attributed to key driving factors such as increase in acceptance of cytokines for cancer and autoimmune therapies and potential contribution in stem cell therapy. However, high cost associated with GMP cytokines therapy is expected to obstruct the growth of the market to a certain extent during the forecast years.

Miltenyi Biotec, Sino Biological Inc.and ABCAM are among the leading companies operating in theAsia Pacific gmp cytokines market.

The report segments in Asia PacificGMP CytokinesMarket as follows:


  • TNF
  • Interleukin
  • Growth Factor
  • Others

By Application

  • Cell and Gene Therapy
  • Tissue-Engineered Products
  • Others

By Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Contact Us
Phone: +1-646-491-9876
Email Id:   


Download Free PDF Brochure